Menu
GWAS Study

Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms.

Melquist S, Craig DW, Huentelman MJ et al.

17357082 PubMed ID
GWAS Study Type
1236 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

MS
Melquist S
CD
Craig DW
HM
Huentelman MJ
CR
Crook R
PJ
Pearson JV
BM
Baker M
ZV
Zismann VL
GJ
Gass J
AJ
Adamson J
SS
Szelinger S
CJ
Corneveaux J
CA
Cannon A
CK
Coon KD
LS
Lincoln S
AC
Adler C
TP
Tuite P
CD
Calne DB
BE
Bigio EH
UR
Uitti RJ
WZ
Wszolek ZK
GL
Golbe LI
CR
Caselli RJ
GN
Graff-Radford N
LI
Litvan I
FM
Farrer MJ
DD
Dickson DW
HM
Hutton M
SD
Stephan DA
Chapter II

Abstract

Summary of the research findings

To date, only the H1 MAPT haplotype has been consistently associated with risk of developing the neurodegenerative disease progressive supranuclear palsy (PSP). We hypothesized that additional genetic loci may be involved in conferring risk of PSP that could be identified through a pooling-based genomewide association study of >500,000 SNPs. Candidate SNPs with large differences in allelic frequency were identified by ranking all SNPs by their probe-intensity difference between cohorts. The MAPT H1 haplotype was strongly detected by this methodology, as was a second major locus on chromosome 11p12-p11 that showed evidence of association at allelic (P<.001), genotypic (P<.001), and haplotypic (P<.001) levels and was narrowed to a single haplotype block containing the DNA damage-binding protein 2 (DDB2) and lysosomal acid phosphatase 2 (ACP2) genes. Since DNA damage and lysosomal dysfunction have been implicated in aging and neurodegenerative processes, both genes are viable candidates for conferring risk of disease.

288 European ancestry cases, 344 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

1236
Total Participants
GWAS
Study Type
Yes
Replicated
213 European ancestry cases, 391 European ancestry controls
Replication Participants
European
Ancestry
U.S., Canada
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.